Canadian Urological Association guideline: Muscle-invasive bladder cancer | Zendy

Girish S. Kulkarni | Zendy; Peter C. Black | Zendy; Srikala S. Sridhar | Zendy; Anil Kapoor | Zendy; Alexandre R. Zlotta | Zendy; Bobby Shayegan | Zendy; Ricardo Rendon | Zendy; Peter Chung | Zendy; Theodorus van der Kwast | Zendy; Nimira Alimohamed | Zendy; Yves Fradet | Zendy; Wassim Kassouf | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Canadian Urological Association guideline: Muscle-invasive bladder cancer

Author(s) -

Girish S. Kulkarni,

Peter C. Black,

Srikala S. Sridhar,

Anil Kapoor,

Alexandre R. Zlotta,

Bobby Shayegan,

Ricardo Rendon,

Peter Chung,

Theodorus van der Kwast,

Nimira Alimohamed,

Yves Fradet,

Wassim Kassouf

Publication year - 2019

Publication title -

canadian urological association journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.477

H-Index - 38

eISSN - 1920-1214

pISSN - 1911-6470

DOI - 10.5489/cuaj.5902

Subject(s) - bladder cancer , guideline , medicine , disease , cancer , presentation (obstetrics) , cystectomy , oncology , pathology , surgery

On average, an estimated 9000 incident cases of bladder cancer are diagnosed in Canada annually.1 Of these, approximately 25% will be muscle-invasive at presentation. Muscle-invasive bladder cancer (MIBC) possesses an aggressive biology that portends metastatic disease. Overall, the five-year mortality of patients diagnosed with localized MIBC is approximately 40–50%.2,3 In the setting of metastatic disease, long-term survival is rare. To help streamline treatment and optimize care, the Canadian Urological Association (CUA) commissioned the creation of a national guideline on MIBC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research